Patient P-02018

Synthetic patientMETA-24 · Day 168 · 25–34 · M · baseline S01Open companion preview

Therapy response

Improving

Tolerance

Deteriorating

GI state

Unstable

Inflammatory state

Unstable

Nutritional resilience

Unstable

Discontinuation risk

74%

Trajectory

Baseline → today → 30-day prediction · hover a day for signals and events

solid = observed · dashed = predicted

Day 0 META-24 started — Baseline state S01
Day 65 Trajectory diverged from prediction — Observed response fell below the model's expected path.
Day 80 GI-04 recommended — GI Support Protocol GI-04
Day 81 Patient accepted — Started GI-04 in the companion
Day 85 ME-01 recommended — Monitoring Escalation ME-01
Day 86 Patient accepted — Started ME-01 in the companion
Day 89 GI symptom burden −25% vs expected — GI Support Protocol GI-04
Day 89 Deterioration detected before clinical escalation — Monitoring Escalation ME-01
Day 95 Tolerance state changed — Unstable → Improving

What changed?

Trajectory began diverging from predicted response on Day 65.

Primary contributors, last 14 days

Nutritional resilience-11
GI instability+10
Toxicity+7
Inflammatory activity+6

What helped?

GI Support Protocol GI-04Day 80
Result: symptom burden −25%
Monitoring Escalation ME-01Day 85
Result: deterioration detected before clinical escalation

LIFE OS recommendation

Supportive Compound SC-12

59%

probability of meaningful tolerance improvement

284 similar trajectories
69% showed improvement
median effect visible after 6 days

Biological layers

Which pathways look influenced, and by which layer of this person's biology.

Pathways under pressure

Mucosal barrier integrity ↓80
- DNAFUT2 non-secretor lowers mucosal fucosylation
- MicrobiomeAkkermansia low → thinner mucus layer
- Daily logGI symptom score 62 and rising
Butyrate / short-chain fatty acid production ↓80
- MicrobiomeButyrate capacity 40/100
- MicrobiomeF. prausnitzii depleted
- Daily logFibre intake low in recent food logs
Inflammatory signalling ↑70
- DNAIL6 -174 variant raises baseline inflammatory tone
- MicrobiomeBacteroides fragilis expansion
- BloodInflammatory load index 59
Autonomic recovery ↓45
- WearableResting HR 83 bpm
- WearableShort sleep window
Drug metabolism and exposure ↑20
- BloodToxicity index 44

DNA

Fictional pharmacogenomic panel

FUT2 rs601338 AA (non-secretor)
Reduced mucosal fucosylation
IL6 -174 G/C
Higher inflammatory tone
CYP2D6 Intermediate metabolizer
Expected exposure

Microbiome

Shannon diversity 2.8 · butyrate capacity 40/100

Akkermansia muciniphilaLow
Faecalibacterium prausnitziiLow
Bacteroides fragilisHigh
Bifidobacterium longumNormal
EnterobacteriaceaeNormal

Wearable, last 14 days

daily evolution fed into the runtime

HRV: 44 ms
Sleep: 6.5 h
Steps: 4,671
Resting HR: 82 bpm

Daily log: GI score 62, nutritional resilience 34, adherence 50.

What this patient sees in NostraAI

The content that steers the trajectory: what to eat, what to do, what to take.

Open companion preview

What to eat

Prepare a plain, low-fat pasta or rice meal and note how it feels afterwards
Choose a freshly cooked, lean protein; avoid frying, rich sauces and leftovers for now
Add one soluble-fibre source (oats, cooked carrots, banana) to breakfast
Eat slowly and stop at comfortable fullness — smaller volume, more often

What to do

Track each bowel movement today: time, stool form, urgency, overnight waking
A 15-minute walk after lunch
Protect a 7.5-hour sleep window; screens off 30 minutes before
Keep hydration steady: small amounts through the day rather than large volumes at once

What to take

Take the dose at the same time relative to your evening meal
Electrolyte solution, one sachet after any loose stool
Fictional demo item: oral nutrition supplement with lunch

284 biologically similar trajectories

Black: this patient. Green: similar patients whose intervention worked. Orange: similar patients where it did not.

Patient	Similarity	Baseline	Intervention	Outcome	Response today
P-02316	53%	S14	GI-04	improved	51
P-02348	52%	S14	GI-04	improved	49
P-02401	52%	S14	GI-04	improved	49
P-02106	51%	S14	GI-04	improved	44
P-02670	51%	S14	SC-12	improved	45
P-02168	50%	S15	GI-04	improved	42
P-02326	50%	S18	NP-02	improved	44
P-02103	49%	S14	GI-04	improved	46
P-02002	48%	S14	GI-04	improved	47
P-02410	48%	S01	GI-04	improved	55
P-02255	47%	S14	GI-04	improved	43
P-02516	47%	S14	SC-12	improved	51